Health
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...
2024-12-13 07:20
1525
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...
2024-12-13 07:20
770
DID YOU HAVE A HIP, KNEE, OR OTHER JOINT REPLACEMENT?
If your implant/replacement involved Exactech products – including Optetrak, Optetrak Logic, Truliant, Vantage, Connexion GXL, and Equinoxe – your attention to this notice is important. NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The following is being issued by Kroll Restructuring Administration L...
2024-12-12 23:19
1467
New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...
2024-12-12 22:08
1684
Bota Bio debuted the 2024 FiE and launched its subsidiary HeliaGenesis, focusing on food and nutrition industries
SAN FRANCISCO and HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The 31st Food Ingredients Europe (referred to as FiE) concluded successfully fromNovember 19th to 21st, 2024, in Frankfurt, Germany. The event brought together over 1,500 ingredient manufacturers and more than 25,000 professional bu...
2024-12-12 22:00
1631
Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital
- A Milestone in Preventive Healthcare and Technological Innovation in Long An TÂN AN CITY, Vietnam, Dec. 12, 2024 /PRNewswire/ -- Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to developVietnam's first AI x ESG Hospital, marking a significant milestone...
2024-12-12 21:23
2016
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
1732
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma
Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life
Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
2024-12-12 21:00
1444
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...
2024-12-12 21:00
1359
Xinhua Silk Road: Pien Tze Huang boosts TCM globalization
BEIJING, Dec. 12, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., aFujian-based traditional Chinese medicine (TCM) company, has been striving to expand its overseas markets, enhancing the influence of TCM in regions such asSoutheast Asia and Europe. Committed to deepening...
2024-12-12 20:43
1839
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...
2024-12-12 18:07
1609
Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services
New collaboration delivers cashless services, as well as access to expedited appointments for outpatient cancer treatment services and independent cancer medical consultation, ensuring comprehensive and convenient protection for customers HONG KONG, Dec. 12, 2024 /PRNewswire/ -- Manulife Hong Ko...
2024-12-12 17:30
1975
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organizati...
2024-12-12 16:30
1470
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...
2024-12-12 16:25
1278
Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results, Net profit rises 152.6% year-on-year
BEIJING, Dec. 12, 2024 /PRNewswire/ -- On December 11, 2024, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the third quarter of 2024 endedSeptember 30, 2024. Duri...
2024-12-12 16:13
2221
RSNA 2024 Spotlight: Careverse Leads the New Trend in Medical AI
CHICAGO, Dec. 12, 2024 /PRNewswire/ -- From December 1st to 5th, 2024, RSNA 2024—the largest and most future-oriented top medical event in the global radiology community, was held inChicago. At this conference, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its ...
2024-12-12 16:04
1002
2024 Design Intelligence Award Held at China Academy of Art, Hangzhou, China
HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The ceremony for the 2024 Design Intelligence Award (DIA) took place onDecember 6 at the Liangzhu Campus of China Academy of Art (CAA). The Fourier General-Purpose Humanoid Robot GR-1 clinched the Grand Award, the highest prize of DIA. Gold Awards we...
2024-12-12 14:17
1237
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion
* Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones * Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® devices inAsia * Transaction highlights R-Bri...
2024-12-12 14:14
3121
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...
2024-12-12 11:48
1838
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) onDecember 13, 2024. The presentation will feature preclinical characterization of LAE11...
2024-12-12 08:30
1190
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 294 media titles]
2025-01-13 10:44
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 287 media titles]
2025-01-14 21:00
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20406
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6498
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5688
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4985
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4966
